Symbols / SXTP $1.78 -4.30% 60 Degrees Pharmaceuticals, Inc.
SXTP Chart
About
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.69M |
| Enterprise Value | 11.79M | Income | -7.37M | Sales | 1.41M |
| Book/sh | -5.25 | Cash/sh | 1.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.23 | PEG | — |
| P/S | 3.33 | P/B | -0.34 | P/C | — |
| EV/EBITDA | -1.54 | EV/Sales | 8.37 | Quick Ratio | 1.77 |
| Current Ratio | 2.66 | Debt/Eq | 4.52 | LT Debt/Eq | — |
| EPS (ttm) | -11.73 | EPS next Y | -7.88 | EPS Growth | — |
| Revenue Growth | 16.20% | Earnings | 2026-03-30 17:00 | ROA | -87.17% |
| ROE | -200.92% | ROIC | — | Gross Margin | 44.52% |
| Oper. Margin | -6.06% | Profit Margin | 0.00% | Shs Outstand | 2.64M |
| Shs Float | 2.34M | Short Float | 19.69% | Short Ratio | 0.15 |
| Short Interest | — | 52W High | 17.68 | 52W Low | 1.29 |
| Beta | — | Avg Volume | 4.65M | Volume | 159.66K |
| Target Price | $17.60 | Recom | Strong_buy | Prev Close | $1.86 |
| Price | $1.78 | Change | -4.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.60
Mean price target
2. Current target
$1.78
Latest analyst target
3. DCF / Fair value
$-33.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.78
Low
$11.20
High
$24.00
Mean
$17.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-27 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-11-28 | main | Ascendiant Capital | Buy → Buy | $3 |
| 2025-09-03 | main | Ascendiant Capital | Buy → Buy | $3 |
| 2025-06-02 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-03-28 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-25 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-10 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-23 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-11 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-09-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-06-06 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-03 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-10-20 | init | HC Wainwright & Co. | — → Neutral | — |
| 2023-10-02 | init | Ascendiant Capital | — → Buy | $2 |
- 60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Fri, 03 Apr 2026 16
- If You Invested $1,000 in 60 degrees pharmaceuticals, Inc. (SXTP) - Stock Titan Mon, 23 Mar 2026 09
- SXTP Forecast, Price Target & Analyst Ratings | 60 DEGREES PHARMA INC (NASDAQ:SXTP) - ChartMill hu, 02 Apr 2026 07
- SXTP Stock Rockets 161% Pre-Market — What Is Driving The Surge? - Stocktwits Fri, 23 Jan 2026 08
- 60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational Developments - Quiver Quantitative ue, 31 Mar 2026 11
- What's Going On With 60 Degrees Pharmaceuticals On Friday? - Benzinga Fri, 13 Mar 2026 07
- 60 Degrees Pharmaceuticals Inc. (SXTP) Receives Buy Rating Upgrade: Key Information You Need - Bitget Fri, 03 Apr 2026 09
- Sales jumped 65%, but 60 Degrees Pharma still lost $7.4M in 2025 - Stock Titan ue, 31 Mar 2026 11
- Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing - Yahoo Finance ue, 23 Dec 2025 08
- $SXTP stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Wed, 28 Jan 2026 08
- Affiliate share ownership restated by 60 Degrees (NASDAQ: SXTP) - Stock Titan Fri, 20 Mar 2026 07
- 60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA - Yahoo Finance ue, 24 Feb 2026 08
- Nasdaq-listed 60 Degrees Pharma shrinks shares 4-for-1 on Jan. 20 reverse - Stock Titan hu, 15 Jan 2026 08
- 60 Degrees (SXTP) updates ATM capacity to $565K after prior sales - Stock Titan Fri, 13 Mar 2026 07
- Malaria prevention pill ARAKODA gets GoodRx discounts at 70,000 pharmacies - Stock Titan Mon, 02 Feb 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.01
+65.49%
|
0.61
+139.61%
|
0.25
+13.60%
|
0.22
|
| Operating Revenue |
|
1.01
+65.49%
|
0.61
+139.61%
|
0.25
+13.60%
|
0.22
|
| Cost Of Revenue |
|
0.78
+103.16%
|
0.38
-18.92%
|
0.47
+9.76%
|
0.43
|
| Reconciled Cost Of Revenue |
|
0.78
+103.16%
|
0.38
-18.92%
|
0.47
+9.76%
|
0.43
|
| Gross Profit |
|
0.22
+0.43%
|
0.22
+200.83%
|
-0.22
-5.65%
|
-0.21
|
| Operating Expense |
|
7.98
-19.68%
|
9.94
+101.43%
|
4.93
+220.10%
|
1.54
|
| Research And Development |
|
2.11
-57.76%
|
4.99
+620.84%
|
0.69
+31.62%
|
0.53
|
| Selling General And Administration |
|
6.28
+24.97%
|
5.03
+18.47%
|
4.24
+225.36%
|
1.30
|
| General And Administrative Expense |
|
6.28
+24.97%
|
5.03
+18.47%
|
4.24
+225.36%
|
1.30
|
| Other Gand A |
|
6.28
+24.97%
|
5.03
+18.47%
|
4.24
+225.36%
|
1.30
|
| Other Operating Expenses |
|
-0.40
-447.13%
|
-0.07
|
—
|
-0.29
|
| Total Expenses |
|
8.76
-15.10%
|
10.32
+90.87%
|
5.41
+174.02%
|
1.97
|
| Operating Income |
|
-7.76
+20.14%
|
-9.72
-88.48%
|
-5.15
-194.47%
|
-1.75
|
| Total Operating Income As Reported |
|
-7.76
+20.14%
|
-9.72
-88.48%
|
-5.15
-194.47%
|
-1.75
|
| EBITDA |
|
-7.28
+7.69%
|
-7.88
-452.67%
|
-1.43
+32.36%
|
-2.11
|
| Normalized EBITDA |
|
-7.54
+21.01%
|
-9.55
-4047.22%
|
0.24
+114.11%
|
-1.71
|
| Reconciled Depreciation |
|
0.08
+30.01%
|
0.06
-36.49%
|
0.10
+27.40%
|
0.08
|
| EBIT |
|
-7.36
+7.39%
|
-7.95
-420.51%
|
-1.53
+30.21%
|
-2.19
|
| Total Unusual Items |
|
0.27
-84.03%
|
1.67
+199.85%
|
-1.67
-323.21%
|
-0.39
|
| Total Unusual Items Excluding Goodwill |
|
0.27
-84.03%
|
1.67
+199.85%
|
-1.67
-323.21%
|
-0.39
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-1.23
-1120.43%
|
0.12
|
| Other Special Charges |
|
—
|
—
|
1.23
+1120.43%
|
-0.12
|
| Net Income |
|
-7.37
+7.32%
|
-7.95
-111.04%
|
-3.77
+39.08%
|
-6.18
|
| Pretax Income |
|
-7.37
+7.38%
|
-7.96
-108.62%
|
-3.81
+38.26%
|
-6.18
|
| Net Non Operating Interest Income Expense |
|
-0.01
+1.35%
|
-0.01
+99.65%
|
-2.29
+42.68%
|
-3.99
|
| Interest Expense Non Operating |
|
0.01
-1.35%
|
0.01
-99.65%
|
2.29
-42.68%
|
3.99
|
| Net Interest Income |
|
-0.01
+1.35%
|
-0.01
+99.65%
|
-2.29
+42.68%
|
-3.99
|
| Interest Expense |
|
0.01
-1.35%
|
0.01
-99.65%
|
2.29
-42.68%
|
3.99
|
| Other Income Expense |
|
0.40
-77.48%
|
1.77
-51.28%
|
3.63
+929.22%
|
-0.44
|
| Other Non Operating Income Expenses |
|
0.13
+30.07%
|
0.10
-98.08%
|
5.30
+12348.84%
|
-0.04
|
| Gain On Sale Of Security |
|
0.27
-84.03%
|
1.67
+481.23%
|
-0.44
+15.13%
|
-0.51
|
| Tax Provision |
|
0.00
|
0.00
-100.00%
|
0.00
-50.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-0.35
-323.21%
|
-0.08
|
| Net Income Including Noncontrolling Interests |
|
-7.37
+7.38%
|
-7.96
-108.60%
|
-3.81
+38.27%
|
-6.18
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.37
+7.32%
|
-7.95
-111.04%
|
-3.77
+39.08%
|
-6.18
|
| Net Income From Continuing And Discontinued Operation |
|
-7.37
+7.32%
|
-7.95
-111.04%
|
-3.77
+39.08%
|
-6.18
|
| Net Income Continuous Operations |
|
-7.37
+7.38%
|
-7.96
-108.60%
|
-3.81
+38.27%
|
-6.18
|
| Minority Interests |
|
0.00
-62.99%
|
0.01
-82.21%
|
0.05
+1322.00%
|
-0.00
|
| Normalized Income |
|
-7.63
+20.62%
|
-9.61
-292.75%
|
-2.45
+58.31%
|
-5.87
|
| Net Income Common Stockholders |
|
-7.37
+7.32%
|
-7.95
-111.04%
|
-3.77
+39.08%
|
-6.18
|
| Diluted EPS |
|
—
|
-74.17
+68.67%
|
-236.72
+11.14%
|
-266.38
|
| Basic EPS |
|
—
|
-74.17
+68.67%
|
-236.72
+11.14%
|
-266.38
|
| Basic Average Shares |
|
—
|
0.11
+546.32%
|
0.02
-28.56%
|
0.02
|
| Diluted Average Shares |
|
—
|
0.11
+546.32%
|
0.02
-28.56%
|
0.02
|
| Diluted NI Availto Com Stockholders |
|
-7.37
+7.32%
|
-7.95
-111.04%
|
-3.77
+39.08%
|
-6.18
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
5.37
-6.83%
|
5.76
-26.01%
|
7.78
+500.04%
|
1.30
|
| Current Assets |
|
4.90
-9.11%
|
5.39
-25.63%
|
7.24
+559.01%
|
1.10
|
| Cash Cash Equivalents And Short Term Investments |
|
1.51
-9.00%
|
1.66
-22.55%
|
2.14
+708.90%
|
0.26
|
| Cash And Cash Equivalents |
|
1.51
-9.00%
|
1.66
-22.55%
|
2.14
+708.90%
|
0.26
|
| Cash Financial |
|
1.51
-9.00%
|
1.66
-22.55%
|
2.14
+708.90%
|
0.26
|
| Receivables |
|
0.51
+4.70%
|
0.49
+110.41%
|
0.23
+403.28%
|
0.05
|
| Accounts Receivable |
|
0.51
+4.70%
|
0.49
+110.41%
|
0.23
+403.28%
|
0.05
|
| Inventory |
|
0.66
+48.37%
|
0.44
-5.02%
|
0.47
-10.11%
|
0.52
|
| Raw Materials |
|
0.08
|
0.00
|
0.00
-100.00%
|
0.40
|
| Work In Process |
|
0.45
+56.89%
|
0.28
+2.11%
|
0.28
+186.18%
|
0.10
|
| Finished Goods |
|
0.39
+144.48%
|
0.16
-15.65%
|
0.19
+1.76%
|
0.18
|
| Prepaid Assets |
|
—
|
—
|
—
|
0.20
|
| Current Deferred Assets |
|
1.24
-28.22%
|
1.73
|
0.00
-100.00%
|
0.07
|
| Other Current Assets |
|
0.98
-8.50%
|
1.07
-75.72%
|
4.40
+2090.71%
|
0.20
|
| Total Non Current Assets |
|
0.47
+26.18%
|
0.37
-31.06%
|
0.54
+173.05%
|
0.20
|
| Net PPE |
|
0.25
+64.45%
|
0.15
+110.17%
|
0.07
+109.97%
|
0.03
|
| Gross PPE |
|
0.44
+46.11%
|
0.30
+36.43%
|
0.22
+36.37%
|
0.16
|
| Accumulated Depreciation |
|
-0.19
-27.72%
|
-0.15
-0.92%
|
-0.15
-16.68%
|
-0.13
|
| Machinery Furniture Equipment |
|
0.07
+6.98%
|
0.07
-9.72%
|
0.07
+376.84%
|
0.02
|
| Other Properties |
|
0.37
+57.14%
|
0.23
+59.40%
|
0.15
+0.60%
|
0.15
|
| Goodwill And Other Intangible Assets |
|
0.22
+42.83%
|
0.16
-30.88%
|
0.23
+38.36%
|
0.16
|
| Other Intangible Assets |
|
0.22
+42.83%
|
0.16
-30.88%
|
0.23
+38.36%
|
0.16
|
| Non Current Prepaid Assets |
|
0.00
-100.00%
|
0.07
-72.73%
|
0.24
|
0.00
|
| Total Liabilities Net Minority Interest |
|
1.99
+10.11%
|
1.80
-39.57%
|
2.99
-88.27%
|
25.45
|
| Current Liabilities |
|
1.84
+11.20%
|
1.66
-41.55%
|
2.84
-88.15%
|
23.92
|
| Payables And Accrued Expenses |
|
1.46
+44.82%
|
1.01
+99.05%
|
0.51
-46.93%
|
0.95
|
| Payables |
|
1.46
+44.82%
|
1.01
+99.05%
|
0.51
-46.93%
|
0.95
|
| Accounts Payable |
|
1.46
+44.82%
|
1.01
+99.05%
|
0.51
-33.28%
|
0.76
|
| Other Payable |
|
—
|
—
|
—
|
—
|
| Total Tax Payable |
|
—
|
—
|
—
|
—
|
| Income Tax Payable |
|
—
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.01
+0.00%
|
0.01
-60.88%
|
0.02
-99.89%
|
21.15
|
| Current Debt |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
-99.96%
|
21.14
|
| Other Current Borrowings |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
-99.95%
|
16.86
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.01
+5.00%
|
0.01
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.33
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.33
|
| Other Current Liabilities |
|
0.37
-41.52%
|
0.64
-72.22%
|
2.31
+54.38%
|
1.49
|
| Total Non Current Liabilities Net Minority Interest |
|
0.14
-2.12%
|
0.15
-2.08%
|
0.15
-90.15%
|
1.53
|
| Long Term Debt And Capital Lease Obligation |
|
0.14
-2.12%
|
0.15
-2.08%
|
0.15
-88.17%
|
1.27
|
| Long Term Debt |
|
0.14
-2.12%
|
0.15
-2.08%
|
0.15
-88.17%
|
1.27
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.26
|
| Non Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.26
|
| Stockholders Equity |
|
3.46
-14.18%
|
4.04
-17.14%
|
4.87
+120.66%
|
-23.58
|
| Common Stock Equity |
|
-6.10
-10.35%
|
-5.53
-10.91%
|
-4.99
+78.84%
|
-23.58
|
| Capital Stock |
|
9.57
+0.00%
|
9.57
-2.95%
|
9.86
+4124607.11%
|
0.00
|
| Common Stock |
|
0.00
+728.57%
|
0.00
+40.00%
|
0.00
-95.82%
|
0.00
|
| Preferred Stock |
|
9.57
+0.00%
|
9.57
-2.95%
|
9.86
|
0.00
|
| Share Issued |
|
1.29
+808.22%
|
0.14
+485.46%
|
0.02
+4.32%
|
0.02
|
| Ordinary Shares Number |
|
1.29
+808.22%
|
0.14
+485.46%
|
0.02
+4.32%
|
0.02
|
| Additional Paid In Capital |
|
41.65
+19.46%
|
34.86
+26.96%
|
27.46
+431.66%
|
5.16
|
| Retained Earnings |
|
-47.89
-18.17%
|
-40.53
-24.39%
|
-32.58
-13.07%
|
-28.82
|
| Gains Losses Not Affecting Retained Earnings |
|
0.14
+5.26%
|
0.14
-0.07%
|
0.14
+83.92%
|
0.07
|
| Minority Interest |
|
-0.08
-3.93%
|
-0.08
-11.88%
|
-0.07
+87.41%
|
-0.57
|
| Other Equity Adjustments |
|
0.14
+5.26%
|
0.14
-0.07%
|
0.14
+83.92%
|
0.07
|
| Total Equity Gross Minority Interest |
|
3.38
-14.55%
|
3.96
-17.57%
|
4.80
+119.87%
|
-24.15
|
| Total Capitalization |
|
3.61
-13.76%
|
4.18
-16.69%
|
5.02
+122.51%
|
-22.31
|
| Working Capital |
|
3.05
-18.14%
|
3.73
-15.39%
|
4.41
+119.31%
|
-22.82
|
| Invested Capital |
|
-5.95
-10.71%
|
-5.38
-11.33%
|
-4.83
-312.22%
|
-1.17
|
| Total Debt |
|
0.15
-2.00%
|
0.16
-9.72%
|
0.17
-99.23%
|
22.42
|
| Net Debt |
|
—
|
—
|
—
|
22.14
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.01
+5.00%
|
0.01
|
| Net Tangible Assets |
|
3.24
-16.49%
|
3.88
-16.46%
|
4.64
+119.56%
|
-23.74
|
| Tangible Book Value |
|
-6.33
-11.24%
|
-5.69
-9.08%
|
-5.22
+78.03%
|
-23.74
|
| Current Notes Payable |
|
—
|
—
|
0.00
-100.00%
|
4.28
|
| Dueto Related Parties Current |
|
—
|
—
|
0.00
-100.00%
|
0.20
|
| Dueto Related Parties Non Current |
|
—
|
—
|
—
|
—
|
| Inventories Adjustments Allowances |
|
-0.25
|
0.00
|
0.00
+100.00%
|
-0.16
|
| Preferred Stock Equity |
|
9.57
+0.00%
|
9.57
-2.95%
|
9.86
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.85
-21.26%
|
-5.65
-24.33%
|
-4.54
-349.80%
|
-1.01
|
| Cash Flow From Continuing Operating Activities |
|
-6.85
-21.26%
|
-5.65
-24.33%
|
-4.54
-349.80%
|
-1.01
|
| Net Income From Continuing Operations |
|
-7.37
+7.38%
|
-7.96
-108.60%
|
-3.81
+38.27%
|
-6.18
|
| Depreciation Amortization Depletion |
|
0.08
+30.01%
|
0.06
-36.49%
|
0.10
+27.40%
|
0.08
|
| Depreciation |
|
0.04
+71.63%
|
0.03
-64.55%
|
0.07
-3.33%
|
0.07
|
| Amortization Cash Flow |
|
0.04
+2.72%
|
0.04
+32.05%
|
0.03
+469.70%
|
0.01
|
| Depreciation And Amortization |
|
0.08
+30.01%
|
0.06
-36.49%
|
0.10
+27.40%
|
0.08
|
| Amortization Of Intangibles |
|
0.04
+2.72%
|
0.04
+32.05%
|
0.03
+469.70%
|
0.01
|
| Other Non Cash Items |
|
—
|
—
|
-4.48
-484.52%
|
1.16
|
| Stock Based Compensation |
|
0.46
-87.35%
|
3.61
+107.85%
|
1.74
|
0.00
|
| Provisionand Write Offof Assets |
|
0.25
|
0.00
+100.00%
|
-0.16
-200.00%
|
0.16
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.11
|
0.00
|
—
|
| Operating Gains Losses |
|
-0.27
+84.03%
|
-1.67
-199.85%
|
1.67
+323.21%
|
0.39
|
| Gain Loss On Investment Securities |
|
-0.27
+84.03%
|
-1.67
-481.23%
|
0.44
-15.13%
|
0.51
|
| Change In Working Capital |
|
-0.01
-102.85%
|
0.19
-52.46%
|
0.41
-87.97%
|
3.37
|
| Change In Receivables |
|
-0.02
+91.04%
|
-0.26
-37.79%
|
-0.19
-284.63%
|
0.10
|
| Changes In Account Receivables |
|
-0.02
+91.04%
|
-0.26
-37.79%
|
-0.19
-284.63%
|
0.10
|
| Change In Inventory |
|
-0.47
-2090.33%
|
0.02
-89.00%
|
0.21
+2001.00%
|
0.01
|
| Change In Prepaid Assets |
|
-0.02
+50.57%
|
-0.04
+92.45%
|
-0.52
-2197.70%
|
0.02
|
| Change In Payables And Accrued Expense |
|
0.50
+5.21%
|
0.48
-54.52%
|
1.05
-63.21%
|
2.86
|
| Change In Accrued Expense |
|
0.01
+149.29%
|
-0.02
-101.87%
|
1.27
-52.88%
|
2.69
|
| Change In Payable |
|
0.49
-2.06%
|
0.50
+333.50%
|
-0.21
-226.32%
|
0.17
|
| Change In Account Payable |
|
0.49
-2.06%
|
0.50
+333.50%
|
-0.21
-226.32%
|
0.17
|
| Change In Other Working Capital |
|
—
|
—
|
-0.10
-123.52%
|
0.43
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.01
+72.85%
|
-0.05
-7.43%
|
-0.05
|
| Investing Cash Flow |
|
0.25
+113.49%
|
-1.89
-1530.12%
|
-0.12
-92.72%
|
-0.06
|
| Cash Flow From Continuing Investing Activities |
|
0.25
+113.49%
|
-1.89
-1530.12%
|
-0.12
-92.72%
|
-0.06
|
| Net PPE Purchase And Sale |
|
-0.14
-34.80%
|
-0.10
-80.09%
|
-0.06
|
0.00
|
| Purchase Of PPE |
|
-0.14
-34.80%
|
-0.10
-80.09%
|
-0.06
|
0.00
|
| Capital Expenditure |
|
-0.22
-20.41%
|
-0.18
-56.28%
|
-0.12
-92.72%
|
-0.06
|
| Capital Expenditure Reported |
|
-0.06
-6.86%
|
-0.05
-29.98%
|
-0.04
-20.93%
|
-0.03
|
| Net Investment Purchase And Sale |
|
0.47
+127.69%
|
-1.71
|
0.00
|
—
|
| Purchase Of Investment |
|
-1.24
+27.69%
|
-1.71
|
0.00
|
—
|
| Sale Of Investment |
|
1.71
|
0.00
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.02
+10.66%
|
-0.03
-38.78%
|
-0.02
+32.46%
|
-0.03
|
| Purchase Of Intangibles |
|
-0.02
+10.66%
|
-0.03
-38.78%
|
-0.02
+32.46%
|
-0.03
|
| Financing Cash Flow |
|
6.44
-8.73%
|
7.05
+8.94%
|
6.47
+429.96%
|
1.22
|
| Cash Flow From Continuing Financing Activities |
|
6.44
-8.73%
|
7.05
+8.94%
|
6.47
+429.96%
|
1.22
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-0.96
-186.98%
|
1.10
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
0.65
-41.18%
|
1.10
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-1.61
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
0.65
-41.18%
|
1.10
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-1.61
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.96
-186.98%
|
1.10
|
| Net Common Stock Issuance |
|
6.45
-8.37%
|
7.04
+11.72%
|
6.30
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-74.42%
|
0.01
-99.03%
|
1.13
|
0.00
|
| Net Other Financing Charges |
|
-0.02
|
—
|
-0.15
-228.89%
|
0.12
|
| Changes In Cash |
|
-0.16
+67.66%
|
-0.48
-126.64%
|
1.82
+1097.79%
|
0.15
|
| Effect Of Exchange Rate Changes |
|
0.01
+1328.26%
|
0.00
-99.19%
|
0.06
+3007.99%
|
-0.00
|
| Beginning Cash Position |
|
1.66
-22.55%
|
2.14
+708.90%
|
0.26
+129.52%
|
0.12
|
| End Cash Position |
|
1.51
-9.00%
|
1.66
-22.55%
|
2.14
+708.90%
|
0.26
|
| Free Cash Flow |
|
-7.07
-21.24%
|
-5.83
-25.12%
|
-4.66
-335.36%
|
-1.07
|
| Interest Paid Supplemental Data |
|
0.01
+0.00%
|
0.01
-95.10%
|
0.18
+8067.67%
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Change In Interest Payable |
|
0.01
+149.29%
|
-0.02
-101.87%
|
1.27
-52.88%
|
2.69
|
| Common Stock Issuance |
|
6.45
-8.37%
|
7.04
+11.72%
|
6.30
|
0.00
|
| Issuance Of Capital Stock |
|
6.45
-8.37%
|
7.04
+11.72%
|
6.30
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-30 View
- 8-K2026-03-20 View
- 8-K2026-03-13 View
- 8-K2026-03-12 View
- 8-K2026-02-12 View
- 8-K2026-01-23 View
- 8-K2026-01-21 View
- 8-K2026-01-08 View
- 42025-12-16 View
- 42025-12-12 View
- 10-Q2025-11-13 View
- 8-K2025-10-10 View
- 42025-09-15 View
- 8-K2025-09-09 View
- 8-K2025-09-05 View
- 42025-08-14 View
- 42025-08-14 View
- 10-Q2025-08-13 View
- 8-K2025-07-18 View
- 42025-06-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|